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Glucose-Regulated Protein 78 (GRP78), also known as BiP (Binding
Immunoglobulin Protein), is a member of the Hsp70 family of chaper-
one proteins that is essential for embryonic development. GRP78 is
highly conserved across species, and is localized primarily in the endo-
plasmic reticulum, where it regulates protein folding and activates the
unfolded protein response pathway (UPR) during stress conditions
[6]. Under normal conditions, GRP78 binds to and inactivates the ER
stress sensors ATF-6, PERK and IRE1. ER stress drives the accumulation
of unfolded proteins to titrate GRP78 away from the stress sensors to-
ward plasma membrane localization. GRP78 is highly expressed on
the cell surface of a variety of cancer types owing to their inherently el-
evated ER stress levels, andweakly expressed on normal cells [8]. Global
profiling of cell surface GRP78 is highly correlated with pathological
states making it a relevant target for therapy.
Several natural ligands can elicit a diverse signaling response upon
binding to cell surface GRP78. On tumor cells, GRP78 can bind to α2-
macroglobulin and Cripto, leading to cell survival and proliferation, or
to Kringle 5 and Par-4, which drives apoptosis [3]. On endothelial
cells, GRP78 interacts with T-cadherin, which promotes cell survival
[8]. Moreover, GRP78 antibodies, designed against the carboxyl-
terminus, induced apoptosis of cancer cells and inhibited the growth
of tumor xenografts [7]. As cell surfaceGRP78 agonists can trigger an ap-
optotic response, a considerable amount of effort has been invested in
generating small molecules that can bind to cell surface GRP78 and ac-
tivate the apoptotic pathways as an effective mode of anticancer ther-
apy. Arap et al. [1] developed two targeted phage peptides containing
predicted binding motifs for GRP78 wherein a dose of 300 mg/mouse
was administered weekly via tail vein for four weeks. The peptides
were tested in nude mice bearing DU145 prostate subcutaneous
tumor xenografts and in immunocompetent Balb/c mice bearing EF43-
fgf4 derived tumors. In both mouse models, the peptides were able to
specifically bind GRP78, undergo cell internalization, and suppress
tumor growth. Bone metastasis targeting peptidomimetic-78 (BMTP-
78), a prototype drug developed by Arap et al. [1], consisting of a
GRP78 binding peptide fused to a death-inducing domain, was tested
in several human leukemia and lymphoma cell lines and toxicological
studies were performed in rodents and nonhuman primates [9]. Re-
markably, BMTP-78 reduced cell viability in 12 cell lines aswell as in pri-
mary human AML cells. However, toxicology data in Sprague Dawley
rats showed dose-dependent toxicity, with kidneys being the most af-
fected organ. Moreover, BMTP-78 was found to be markedly toxic to
non-human primates, causing fatal cardiac dysfunction. Although
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GRP78 is an attractive therapeutic target, these findings underscored
the need for developing safer molecules.
The study by Kao and collaborators [5] published in this issue, de-
scribes a peptide that not only specifically targets GRP78 and suppresses
tumor growth, but also accumulates in the tumormicroenvironment for
up to 72 h post-injection, with no apparent liver or kidney toxicity in
mice. The group had previously identified isthmin (ISM), an
antiangiogenic and proapoptotic protein that was able to bind both
GRP78 and αvβ5 integrin on the plasma [4]. ISM is internalized in can-
cer cells, where it co-localizes with GRP78, but not αvβ5 integrin, and
leads to apoptosis in B16F10 and 4 T1 tumor cells. ISM contains two do-
mains: TSR (thrombospondin type I repeat) and C-terminal AMOP (ad-
hesion-associated domain in MUC and other proteins), of which AMOP
seems to be more critical for the function of ISM as mutation of critical
residues in AMOP (KD316–317) results in ablation of its activity. Kao
et al. used the AMOP domain, known to induce apoptosis of HUVECs
cells, to design cyclic peptides that target GRP78. All 16 synthetic pep-
tides harbored the RKD core domain of AMOP and displayed
proapoptotic activity. BC71 peptide exhibited the highest apoptotic ac-
tivity toward HUVEC cells and decreased cell viability. Using neutraliz-
ing antibodies to N-terminal GRP78, C-terminal GRP78 and to αvβ5
integrin, the authors demonstrated that BC71 induced apoptosis by
interacting with the N-terminal portion of GRP78 since only N-
terminal GRP78 antibody was able to reduce apoptosis triggered by
BC71. In accordance with observations from different groups on extra-
cellular ligands of GRP78, BC71 leads to apoptosis via caspase-8 and
p53 activation, as chemical inhibition of these targets decreased BC71-
induced apoptosis by more than 50%. Tracking in vivo distribution fol-
lowing intravenous injection of the peptide into mice, Kao and col-
leagues demonstrated that Cy7-labelled BC71 accumulated in the
area surrounding the 4 T1 mammary tumors in mice for at least
72 h post-injection. Reduced angiogenesis and extensive apoptosis,
as indicated by TUNEL positivity, was observed upon treatment. Al-
though preliminary toxicity results are promising, it needs further
investigation as the peptide was tested in a single model. However,
the anti-tumor efficacy of targeting cell surface GRP78 is consistent
with previous studies and this article sheds new light on the anti-
angiogenic effects of the treatment. Another interesting application
is the use of the peptides as imaging agents or drug carriers since
exploiting their ability to target tumor cells as-well-as endothelial
cells surrounding the tumor.
It is noteworthy that, although targeting of GRP78 is promising and
was shown to be efficient in suppressing tumor growth, this effect is
limited to the extent of GRP78 expression on the cell surface. Regulation
of NF-κB has been shown to induce ER stress andGRP78 translocation to
the cell surface [2, 10]. However, it also causes immunosuppression and
tumor cell immune evasion. Development of new strategies that com-
bine agents that increase GRP78 translocation to the cell surface with
peptides or small molecules targeting GRP78 could significantly im-
prove the efficacy of cancer treatment.
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